Molfenter Todd, Vechinski Jessica, Kim Jee-Seon, Zhang Jingru, Meng Lionel, Tveit Jessica, Madden Lynn, Taxman Faye S
University of Wisconsin, 1513 University Ave, Madison, WI, 53706, USA.
University of Wisconsin, 1025 W. Johnson St, Madison, WI, 53706, USA.
Implement Sci. 2025 Feb 3;20(1):7. doi: 10.1186/s13012-025-01419-6.
For nearly two decades, it has been widely recognized that individuals in jail settings have a high prevalence of opioid use disorders (OUD) and are highly susceptible to fatal overdose upon their release. This setting provides a public health opportunity to address OUD with Medication for Opioid Use Disorders (MOUDs). Yet, 56% of jails do not provide MOUD, creating a pressing need for better implementation approaches in jail and the hand-off to the community. Two successful implementation strategies, NIATx external coaching and the Extension for Community Healthcare Outcomes (ECHO) case management telementoring model, were compared to address this persistent treatment gap.
This 2 × 2 design compared high (n = 12) and low (n = 4) dose coaching with and without ECHO in a 12-month intervention and 12 M sustainability period. The national trial included 25 jails and 13 community-based partners. MOUD trends for buprenorphine, methadone, injectable naltrexone, and combined MOUD between the study arms were assessed.
Jail sizes ranged from 24% with < 100 and 24% with > 500 daily population, and community-based treatment providers ranged from 63% with < 50 and 7% with > 500 average monthly OUD intakes. New patient counts were found to significantly increase across the intervention phase for buprenorphine (p < .01) and combined MOUD (p < .01). Injectable naltrexone and methadone showed no consistent, significant gains. For sites with low coaching without ECHO, new patient counts for combined MOUD were predicted to increase by 47.44% during the intervention phase and 7.30% during the sustainability phase. ECHO demonstrated that MOUD use did not significantly increase compared to coaching across MOUDs in the intervention phase (p = .517). High- and low-dose coaching showed no significant differences in MOUD use during the intervention phase (p = .124).
Coaching emerged as a more effective implementation strategy than ECHO for increasing buprenorphine use in jail settings. In practice, ECHO sessions offered considerable overlap with coaching strategies. While high-dose coaching had greater gains for MOUDs overall than low-dose coaching, those gains were statistically insignificant, suggesting low-dose coaching to be more economical. To increase MOUD use in jail settings, jurisdictions should focus on new MOUDs so all three MOUDs are available and enhance the post-incarceration continuum of care.
Name of registry: ClinicalTrials.gov.
NCT04363320. Date of registration: 2020-07-30. URL of trial registry record: https://clinicaltrials.gov/study/NCT04363320?term=molfenter&rank=7 .
近二十年来,人们普遍认识到,监狱中的个体阿片类药物使用障碍(OUD)患病率很高,且在获释后极易发生致命性过量用药。这种情况为通过阿片类药物使用障碍药物治疗(MOUDs)来解决OUD提供了一个公共卫生契机。然而,56%的监狱未提供MOUD,这迫切需要在监狱中采用更好的实施方法,并做好向社区的交接工作。为解决这一持续存在的治疗差距,对两种成功的实施策略进行了比较,即NIATx外部指导和社区医疗保健成果扩展(ECHO)病例管理远程指导模式。
采用2×2设计,在为期12个月的干预期和12个月的可持续性阶段,比较了有和没有ECHO的高剂量(n = 12)和低剂量(n = 4)指导。全国性试验包括25所监狱和13个社区合作伙伴。评估了研究组之间丁丙诺啡、美沙酮、注射用纳曲酮以及联合使用MOUD的趋势。
监狱规模方面,24%的监狱每日人口少于100人,24%的监狱每日人口多于500人;社区治疗提供者方面,63%的机构平均每月OUD摄入量少于50人,7%的机构平均每月OUD摄入量多于500人。在干预阶段,丁丙诺啡(p <.01)和联合使用MOUD(p <.01)的新患者数量显著增加。注射用纳曲酮和美沙酮没有呈现出一致的显著增长。对于没有ECHO的低剂量指导的场所,联合使用MOUD的新患者数量预计在干预阶段增加47.44%,在可持续性阶段增加7.30%。ECHO表明,与干预阶段各MOUD的指导相比,MOUD的使用没有显著增加(p = 0.517)。高剂量和低剂量指导在干预阶段MOUD的使用上没有显著差异(p = 0.124)。
在监狱环境中,指导被证明是一种比ECHO更有效的增加丁丙诺啡使用的实施策略。在实践中,ECHO会议与指导策略有相当多的重叠。虽然高剂量指导总体上比低剂量指导在MOUD方面有更大的收益,但这些收益在统计学上并不显著,这表明低剂量指导更经济。为了增加监狱环境中MOUD的使用,各司法管辖区应关注新型MOUD,使所有三种MOUD都可用,并加强监禁后的连续护理。
注册机构名称:ClinicalTrials.gov。
NCT04363320。注册日期:2020年7月30日。试验注册记录的网址:https://clinicaltrials.gov/study/NCT04363320?term=molfenter&rank=7 。